biei resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

## Acinetobacter baumannii, Strain MRSN 1187

#### Catalog No. NR-52156

This reagent is the tangible property of the U.S. Government.

#### **Product Description:**

Acinetobacter baumannii (A. baumannii), strain MRSN 1187 was isolated in 2010 from a human wound in the United States as part of a global surveillance program. A. baumannii, strain MRSN 1187 was deposited as sensitive to colistin, imipenem, meropenem, and tetracycline and resistant to amikacin, ceftazidime, ciprofloxacin, ceftriaxone, gentamicin, trimethoprim/sulfamethoxazole, levofloxacin, tobramycin, and ampicillin/sulbactam, with intermediate resistance to cefepime. NR-52156 lot 70051443 was produced by inoculation of BEI Resources seed lot 70039387 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy broth for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

#### Lot: 70051443

## Manufacturing Date: 24MAR2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: <u>Contact@BEIResources.org</u>. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS	
Phenotypic Analysis			
Cellular morphology	Gram-negative rods	Gram-negative rods	
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)	
Growth at 44°C ± 2°C <sup>1</sup> 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth		
Motility Remel™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Non-motile	
VITEK <sup>®</sup> MS (MALDI-TOF)	A. baumannii	A. baumannii (99.9%)	
Antibiotic Susceptibility Profile <sup>2,3</sup>			
Amikacin	Resistant	Resistant (96 µg/mL)	
Ampicillin/sulbactam	Resistant	Intermediate (12 µg/mL) <sup>4</sup>	
Cefepime	Intermediate	Intermediate (16 µg/mL)	
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)	
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)	
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)	
Colistin	Sensitive	Sensitive (≤ 0.25 µg/mL) <sup>5</sup>	
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)	
Imipenem	Sensitive	Sensitive (2 µg/mL)	
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)	
Meropenem	Sensitive	Sensitive (1 µg/mL)	
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)	
Tobramycin	Resistant	Resistant (32 µg/mL)	
Tetracycline	Sensitive	Intermediate (8 µg/mL) <sup>6</sup>	
Genotypic Analysis			
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to <i>A. baumannii</i> , strain MRSN 1187 (GenBank: VHHC01000094.1)	99.9% sequence identity to <i>A. baumannii</i> , strain MRSN 1187 (GenBank: VHHC01000094.1)	
Purity	Growth consistent with expected		
7 days at 37°C in an aerobic atmosphere with and without 5% CO <sub>2</sub> on Tryptic Soy agar	colony morphology	colony morphology	

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898

# bieii resources

# **Certificate of Analysis for NR-52156**

SUPPORTING INFECTIOUS DISEASE RESEARCH

TEST	SPECIFICATIONS	RESULTS
Viability	Growth	Growth

<sup>1</sup>Growth at 44°C differentiates A. baumannii from A. calcoaceticus and A. pittii, which do not grow at 44°C.

<sup>2</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

<sup>3</sup>Antibiotic susceptibility was tested using a combination of VITEK<sup>®</sup>2 GN81, and E-test strips.

<sup>4</sup>A. baumannii, strain MRSN 1187 was deposited as resistant to ampicillin/sulbactam but showed a MIC of 12 µg/mL (interpreted as intermediate) for ampicillin/sulbactam during QC testing. Testing was performed in duplicate.

<sup>5</sup>Testing was performed on BEI Resources seed lot 70039387.

<sup>6</sup>The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

State States	14 ind	
	15	
8		
60		

## Figure 1: Colony Morphology

# /Sonia Bjorum Brower/ Sonia Bjorum Brower

Technical Manager or designee, ATCC Federal Solutions

ATCC<sup>®</sup>, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC<sup>®</sup>'s knowledge.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.



05 DEC 2022